| P2093 | author name string | Antonis Valachis | |
| | Nikolaos P Polyzos | |
| | Davide Mauri | |
| | Antonios Garras | |
| | Christodoulos Neophytou | |
| | Evangelos G Papanikolau | |
| | Lampriani Tsali | |
| P2860 | cites work | Association between glutathione S-transferase pi polymorphisms and survival in patients with advanced nonsmall cell lung carcinoma | Q81602705 |
| | Pharmacogenetic profiling and clinical outcome of patients with advanced gastric cancer treated with palliative chemotherapy | Q83170875 |
| | Association of GSTP1 polymorphism and survival for esophageal cancer | Q95820187 |
| | ERCC2 2251A>C genetic polymorphism was highly correlated with early relapse in high-risk stage II and stage III colorectal cancer patients: a preliminary study | Q21260394 |
| | Glutathione S-transferase M1 null genotype: lack of association with tumour characteristics and survival in advanced breast cancer. | Q24791151 |
| | XRCC1 R399Q polymorphism is associated with response to platinum-based neoadjuvant chemotherapy in bulky cervical cancer | Q27851395 |
| | Genetic determinants of lung cancer short-term survival: the role of glutathione-related genes | Q28201239 |
| | Citation bias of hepato-biliary randomized clinical trials | Q28212007 |
| | Cholesterol lowering trials in coronary heart disease: frequency of citation and outcome | Q29029379 |
| | Publication bias in clinical research | Q29541186 |
| | A multivariate analysis of genomic polymorphisms: prediction of clinical outcome to 5-FU/oxaliplatin combination chemotherapy in refractory colorectal cancer | Q31080865 |
| | Susceptibility and outcome in oral cancer: preliminary data showing an association with polymorphism in cytochrome P450 CYP2D6. | Q31968968 |
| | Modified FOLFOX-6 chemotherapy in advanced gastric cancer: Results of phase II study and comprehensive analysis of polymorphisms as a predictive and prognostic marker | Q33337970 |
| | A phase II study of irinotecan and carboplatin in advanced non-small cell lung cancer with pharmacogenomic analysis: final report | Q33374788 |
| | Pharmacogenetic analyses of a phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil and leucovorin plus either oxaliplatin or cisplatin: a study of the arbeitsgemeinschaft internistische onkologie | Q33424261 |
| | Role of glutathione-S-transferase and codon 72 of P53 genotypes in epithelial ovarian cancer patients | Q33997001 |
| | Journal prestige, publication bias, and other characteristics associated with citation of published studies in peer-reviewed journals | Q34661986 |
| | Genetic associations: false or true? | Q35119636 |
| | Glutathione S-transferase gene polymorphisms and risk and survival of pancreatic cancer | Q35842688 |
| | Genetic association studies in epilepsy: "the truth is out there". | Q35929994 |
| | Serum IgE, tumor epidermal growth factor receptor expression, and inherited polymorphisms associated with glioma survival | Q36450938 |
| | Polymorphisms in sulfotransferase 1A1 and glutathione S-transferase P1 genes in relation to colorectal cancer risk and patients' survival | Q36491575 |
| | Polymorphisms of glutathione S-transferases (GST) and thymidylate synthase (TS)--novel predictors for response and survival in gastric cancer patients | Q36613622 |
| | Glutathione S-transferases (GSTT1 and GSTM1) gene deletions in Tunisians: susceptibility and prognostic implications in breast carcinoma | Q36671235 |
| | Factors influencing publication of research results. Follow-up of applications submitted to two institutional review boards | Q36728722 |
| | Pharmacogenetic prediction of clinical outcome in advanced colorectal cancer patients receiving oxaliplatin/5-fluorouracil as first-line chemotherapy | Q36936011 |
| | GSTP1 Ile105Val polymorphism correlates with progression-free survival in MCRC patients treated with or without irinotecan: a study of the Dutch Colorectal Cancer Group. | Q36943992 |
| | XRCC1 Arginine194Tryptophan and GGH-401Cytosine/Thymine polymorphisms are associated with response to platinum-based neoadjuvant chemotherapy in cervical cancer | Q37292735 |
| | The role of glutathione-S-transferase polymorphisms in ovarian cancer survival | Q38435382 |
| | Polymorphisms in glutathione S-transferases (GSTM1 and GSTT1) and survival after treatment for breast cancer | Q38459487 |
| | Glutathione S-transferase M1, T1, and P1 polymorphisms and survival among lung cancer patients. | Q40580224 |
| | Lack of association of GSTT1, GSTM1, GSTO1, GSTP1 and CYP1A1 polymorphisms for susceptibility and outcome in Brazilian prostate cancer patients. | Q43512018 |
| | Glutathione S-transferase GSTM1 and GSTT1 genotypes in ovarian cancer: association with p53 expression and survival | Q43591941 |
| | Glutathione-associated enzymes in head and neck squamous cell carcinoma and response to cisplatin-based neoadjuvant chemotherapy. | Q43690877 |
| | Glutathione S-transferase polymorphisms and survival in primary malignant glioma | Q43690923 |
| | Association between glutathione S-transferase P1, T1, and M1 genetic polymorphism and survival of patients with metastatic colorectal cancer | Q44033535 |
| | Drug-metabolizing enzyme polymorphisms predict clinical outcome in a node-positive breast cancer cohort | Q44165395 |
| | Association between a glutathione S-transferase A1 promoter polymorphism and survival after breast cancer treatment | Q44271228 |
| | Platinum/paclitaxel-based chemotherapy in advanced ovarian carcinoma: glutathione S-transferase genetic polymorphisms as predictive biomarkers of disease outcome | Q44507310 |
| | Glutathione-S-transferase P1, T1 and M1 genetic polymorphisms in neoadjuvant-treated locally advanced gastric cancer: GSTM1-present genotype is associated with better prognosis in completely resected patients | Q44544185 |
| | TGFbeta1 (Leu10Pro), p53 (Arg72Pro) can predict for increased risk for breast cancer in south Indian women and TGFbeta1 Pro (Leu10Pro) allele predicts response to neo-adjuvant chemo-radiotherapy | Q44806723 |
| | Association between glutathione-S-transferase GSTP1 genotypes, GSTP1 over-expression, and outcome in epithelial ovarian cancer | Q44846172 |
| | Associations between drug metabolism genotype, chemotherapy pharmacokinetics, and overall survival in patients with breast cancer | Q44912735 |
| | Genetic polymorphisms in glutathione-S-transferase genes (GSTM1, GSTT1, GSTP1) and survival after chemotherapy for invasive breast carcinoma | Q45163885 |
| | Genotypes of TNF-alpha, VEGF, hOGG1, GSTM1, and GSTT1: useful determinants for clinical outcome of bladder cancer | Q45236380 |
| | Glutathione S-transferase polymorphisms and survival from head and neck cancer | Q45237112 |
| | Role of xenobiotic metabolizing gene polymorphisms in breast cancer susceptibility and treatment outcome. | Q45278599 |
| | Polymorphism in cytochrome P450 2A6 and glutathione S-transferase P1 modifies head and neck cancer risk and treatment outcome. | Q46030329 |
| | DNA repair gene polymorphisms predict favorable clinical outcome in advanced non-small-cell lung cancer | Q46052831 |
| | Polymorphisms in p53, GSTP1 and XRCC1 predict relapse and survival of gastric cancer patients treated with oxaliplatin-based adjuvant chemotherapy. | Q46106796 |
| | Genetic polymorphisms affecting clinical outcomes in epithelial ovarian cancer patients treated with taxanes and platinum compounds: a Korean population-based study | Q46128074 |
| | Glutathione-S-transferase pi (GSTP1) codon 105 polymorphism is not associated with oxaliplatin efficacy or toxicity in advanced colorectal cancer patients | Q46197317 |
| | GSTM, GSTT and p53 polymorphisms as modifiers of clinical outcome in colorectal cancer. | Q46481703 |
| | Predictive biomarkers of chemotherapy efficacy in colorectal cancer: results from the UK MRC FOCUS trial | Q46570394 |
| | Influential factors on tumor recurrence in head and neck cancer patients | Q46589373 |
| | Glutathione S-transferase M1, T1 and P1 polymorphisms: susceptibility and outcome in lung cancer patients. | Q46600897 |
| | Glutathione S-transferase T1 polymorphisms are associated with outcome in colorectal cancer | Q46624523 |
| | Molecular prognosticators and genomic instability in papillary thyroid cancer | Q46644899 |
| | Glutathione S-transferase polymorphisms and ovarian cancer treatment and survival | Q46731534 |
| | Polymorphisms in the glutathione S-transferase mu cluster are associated with tumour progression and patient outcome in colorectal cancer. | Q46835660 |
| | Multiple Genetic Polymorphisms of GSTP1 313AG, MDR1 3435CC, and MTHFR 677CC highly correlated with early relapse of breast cancer patients in Taiwan. | Q46840044 |
| | Determination of ERCC2 Lys751Gln and GSTP1 Ile105Val gene polymorphisms in colorectal cancer patients: relationships with treatment outcome | Q46845988 |
| | Influence of germline polymorphisms of GSTT1, GSTM1, and GSTP1 in familial versus sporadic breast cancer susceptibility and survival | Q46850281 |
| | L-MYC and GSTM1 polymorphisms are associated with unfavourable clinical parameters of gliomas. | Q46875977 |
| | Pharmacogenetic assessment of toxicity and outcome after platinum plus taxane chemotherapy in ovarian cancer: the Scottish Randomised Trial in Ovarian Cancer | Q46958963 |
| | Polymorphisms in manganese superoxide dismutase, myeloperoxidase and glutathione-S-transferase and survival after treatment for metastatic breast cancer. | Q46961622 |
| | Paclitaxel, carboplatin, 5-fluorouracil, and radiation for locally advanced esophageal cancer: phase II results of preliminary pharmacologic and molecular efforts to mitigate toxicity and predict outcomes: North Central Cancer Treatment Group (N0044 | Q46962026 |
| | Analysis of L-myc and GSTM1 genotypes in Chinese non-small cell lung carcinoma patients. | Q50986071 |
| | Publication bias. | Q52877651 |
| | Genomic profiling associated with recurrence in patients with rectal cancer treated with chemoradiation. | Q53644294 |
| | The glutathione S-transferase M1 genotype in ovarian cancer. | Q54046914 |
| | CYP2E1 polymorphism, cigarette smoking, p53 expression, and survival in non-small cell lung cancer: a long term follow-up study. | Q54693803 |
| | Polymorphisms inNQO1and the clinical course of urinary bladder neoplasms | Q57664832 |
| | Effect of germ-line genetic variation on breast cancer survival in a population-based study | Q64387842 |
| | Prognostic significance of germ line polymorphisms of the CYP1A1 and glutathione S-transferase genes in patients with non-small cell lung cancer | Q71254262 |
| | Association between survival after treatment for breast cancer and glutathione S-transferase P1 Ile105Val polymorphism | Q73144127 |
| | Single tube multiplex polymerase chain reaction genotype analysis of GSTM1, GSTT1 and GSTP1: relation of genotypes to TP53 tumor status and clinicopathological variables in breast cancer patients | Q77590852 |
| | p53 mutation spectrum in relation to GSTM1, CYP1A1 and CYP2E1 in surgically treated patients with non-small cell lung cancer | Q77903851 |
| | Glutathione S-transferase GSTP1 genotypes are associated with response to androgen ablation therapy in advanced prostate cancer | Q78765497 |
| | Genetic variations in radiation and chemotherapy drug action pathways predict clinical outcomes in esophageal cancer | Q79754864 |
| | Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFOX-4 chemotherapy | Q80076968 |
| | Glutathione-S-transferase P1 isoenzyme polymorphisms, platinum-based chemotherapy, and non-small cell lung cancer | Q80100879 |
| | Polymorphisms in the glutathione S-transferase M1, T1, and P1 genes and prostate cancer prognosis | Q80143767 |
| | The association between polymorphisms in glutathione S-transferase (GSTM1 and GSTT1) and lung cancer outcome | Q80184033 |
| | Favorable genetic polymorphisms predictive of clinical outcome of chemoradiotherapy for stage II/III esophageal squamous cell carcinoma in Japanese | Q80434021 |
| | Polymorphism of XRCC1 predicts overall survival of gastric cancer patients receiving oxaliplatin-based chemotherapy in Chinese population | Q80532477 |
| | Polymorphisms in genes encoding drug metabolizing enzymes and their influence on the outcome of children with neuroblastoma | Q80799133 |
| | Negative results and impact factor: a lesson from neonatology | Q81454811 |
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | single-nucleotide polymorphism | Q501128 |
| | translational medicine | Q17112037 |
| P304 | page(s) | 492-500 | |
| P577 | publication date | 2011-08-24 | |
| P1433 | published in | International Journal of Medical Sciences | Q10927439 |
| P1476 | title | Translational medicine and reliability of single-nucleotide polymorphism studies: can we believe in SNP reports or not? | |
| P478 | volume | 8 | |